IRB #

STUDY00020485

Title

[NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA

Principal Investigator

Craig Okada

Study Purpose

This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to treat the cancer

Medical Condition(s)

Hodgkin Lymphoma

Eligibility Criteria

Participants must be at least 18 years old, have newly diagnosed, previously untreated Stage III or IV classical Hodgkin lymphoma.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive study drug for approximately 6 months. Follow up will last up to 10 years.

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

SWOG

Recruitment End

09/03/2029

Compensation Provided

No


Go Back